Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents

Author(s): K. M. Bompiani, R. S. Woodruff, R. C. Becker, S. M. Nimjee, B. A. Sullenger

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 10 , 2012

Become EABM
Become Reviewer
Call for Editor


Aptamers, or nucleic acid ligands, have gained clinical interest over the past 20 years due to their unique characteristics, which are a combination of the best facets of small molecules and antibodies. The high binding affinity and specificity of aptamers allows for isolation of an artificial ligand for theoretically any therapeutic target of interest. Chemical manipulations of aptamers also allow for fine-tuning of their bioavailability, and antidote control greatly expands their clinical use. Here we review the various methods of antidote control of aptamer therapeutics – matched oligonucleotide antidotes and universal antidotes. We also describe the development, recent progress, and potential future therapeutic applications of these types of aptamer-antidote pairs.

Keywords: Anticoagulant, antidote, antiplatelet, aptamer, oligonucleotide antidote, therapeutic, universal antidote, nucleic acid ligands, small molecules, antibodies, aptamer-antidote pairs, viral RNA, oligonucleotides, therapeutic target, clinical interest.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 23 July, 2012
Page: [1924 - 1934]
Pages: 11
DOI: 10.2174/138920112802273137
Price: $65

Article Metrics

PDF: 8